Download full-text PDF

Source

Publication Analysis

Top Keywords

cox-1 sparing
4
sparing cox-2
4
cox-2 inhibitory
4
inhibitory drugs
4
drugs renal
4
renal hepatic
4
hepatic safety
4
safety tolerability
4
tolerability profiles
4
profiles celecoxib
4

Similar Publications

Article Synopsis
  • mPGES-1 is highlighted as a key target for developing treatments for inflammation and pain, with the study introducing new benzimidazole compounds that effectively inhibit this enzyme.
  • One of the compounds, AGU654, showed exceptional selectivity for mPGES-1 over other related enzymes, with a low inhibition concentration (IC = 2.9 nM) and promising bioavailability.
  • AGU654 was able to reduce PGE production from activated immune cells without affecting other prostaglandins, and it also demonstrated success in alleviating fever and pain in guinea pig models, indicating its potential for managing inflammatory diseases.
View Article and Find Full Text PDF

Non-steroidal anti-inflammatory drugs (NSAIDs), the most highly prescribed drugs in the world for the treatment of pain, inflammation, and fever, cause gastric mucosal damage, including ulcers, directly or indirectly, by which the development of GI-safer (-sparing) NSAIDs relates to unmet medical needs. This study aimed to document the preventive effects of walnut polyphenol extracts (WPEs) against NSAID-induced gastric damage along with the molecular mechanisms. RGM-1 gastric mucosal cells were administered with indomethacin, and the expressions of the inflammatory mediators between indomethacin alone or a combination with WPEs were compared.

View Article and Find Full Text PDF

The gut mucosal barrier plays a key role in the physiology of gastrointestinal (GI) tract, preventing under homeostatic conditions, the epithelial cells of the gastric mucosa from hydrochloric acid and intestinal mucosa from alkaline secretion, food toxins and pathogenic microbiota. Previous studies have documented that blockade of both isoforms of cyclooxygenase (COX): constitutive (COX-1) and inducible (COX-2), as well NO synthase in the stomach exacerbated the gastric damage induced by various ulcerogens, however, such as effects of non-selective and selective inhibition of COX-1, COX-2 and NOS enzymes on colonic damage have been little studied. The supplementation of NO by intragastric (i.

View Article and Find Full Text PDF

Introduction: Prostaglandin E (PGE) is produced by cyclooxygenases (COX-1/2) and the microsomal prostaglandin E synthase 1 (mPGES-1). PGE is pro-inflammatory in diseases such as rheumatoid arthritis, cardiovascular disorders, and cancer. While Nonsteroidal anti-inflammatory drugs (NSAIDs) targeting COX can effectively reduce inflammation, their use is limited by gastrointestinal and cardiovascular side effects resulting from the blockade of all prostanoids.

View Article and Find Full Text PDF

Cyclooxygenase (COX) and Lipoxygenase (LOX) are essential enzymes for arachidonic acid (AA) to eicosanoids conversion. These AA-derived eicosanoids are essential for initiating immunological responses, causing inflammation, and resolving inflammation. Dual COX/5-LOX inhibitors are believed to be promising novel anti-inflammatory agents.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!